Grade My Investments
HomeFree Stock Grades › STRO

Sutro Biopharma, Inc. (STRO) Stock Grade

STRO · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$98.3M
P/E Ratio
Revenue Growth (YoY)
+65.2%
Net Margin
-186.5%
Return on Equity
144.3%
Dividend Yield
None

About Sutro Biopharma, Inc.'s fundamentals

Sutro Biopharma is a small-cap biotechnology company with a market capitalization of $98.3 million that is experiencing strong revenue growth at 65.2% year-over-year. However, the company is currently unprofitable, posting a net margin of -186.5% and reporting a net loss in its latest annual statement, which reflects typical early-stage biotech operations. The company does not pay a dividend, consistent with its focus on reinvesting capital into research and development rather than returning cash to shareholders.

Track STRO free — no credit card required. Live grade + monthly AI report →